Aarti Pharmalabs Ltd (AARTIPHARM) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management maintains its ambitious 40-50% revenue growth guidance for the CDMO business in FY27, implying a significant ramp-up to 280-300 crores in H2.
- The company is entering the complex peptide and oligonucleotide space, with a lab expected to be operational by year-end and commercial activities targeted for FY28.
- Capex for FY27 is guided at 350-400 crores, and total debt is expected to rise further from the current 650-660 crores to fund this expansion.
Performance Overview
- Aarti Pharmalabs delivered its highest ever quarterly revenue, showcasing strong growth momentum.
- The company is making healthy progress across all business segments: Xanthine Derivatives, API & Intermediates, and CDMO/CMO.
- Management highlighted the execution of its growth strategy to solidify its position as a preferred partner in the global pharmaceutical supply chain.
- The mature Xanthine segment is positioned as a cash cow, while the CDMO/CMO pillar is identified as the key driver for accelerated future growth.
- Ongoing capacity expansions, particularly in Xanthine and at the Atali site, are progressing as planned and are set to drive future value creation.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.